Unbiased Analysis of Today's Healthcare Issues
Medicaid reimbursement access and health outcomes. Where to move to in old age. The cost of Alzheimer’s to Medicaid managed care. The impact of the soda tax. Hospital Readmissions Reduction Program performance explained: “74.3% to 86.5% of the improvement in ERRs [excess readmission ratio] for penalized hospitals was explained by RTM [regression to the mean].”
Deaths due to lack of health insurance. Drugs vs. stents. New investment idea? Workers comp is doing great or a big problem? Health system comparison: Germany vs. US.
Does anyone know what ‘value-based care’ means? A tale of two networks. “$540,841.90 for 14 weeks of dialysis care” Can we really finance Warren’s Medicare-for-all? California air quality over time.
Deficit nears $1 trillion. Pelosi’s reference pricing bill. Gates Foundation to develop gene therapies. Was the ACA anti-marriage? Physician payment and lab test ordering. Patent buy-outs.
Gene therapies on the rise. No rebate drug markets? California health hazards. Exercise and dementia. BC/BS: Single payer = salad bar? …and the NBA season has started!
What is Civica Rx? NPC on ICER’s revised value framework. Trebek and cancer. Rx for abstinence? Changing health policy landscape on pharmaceutical pricing.
The right to know. NPs vs. MDs. The cause of vaping lung damage. Hospitals getting into the housing business?“…of the 26 occupations…identified as ‘highly offshorable’ …15 have added jobs over the past decade and 11 have cut them.” Wellness doesn’t work.
Free college tuition? Tennessee to turn Medicaid into a block grant? Was there a white collar job apocalypse? Does automatic re-enrollment matter for Obamacare plan uptake? How will national health reform affect workers comp?
Third World > First World. Ebola and economics. £200m for UK BioBank. Reversing aging. Is PFI the future for MedicareForAll?
Much of my blog discusses the value of new, innovative treatments. In the current patent environment, drug patents expire and low cost generics enter the market. This results in huge surplus value accruing to consumers. However, those benefits only occur if the supply of effective, low-cost generic medication reach patients. Unfortunately, that is not always…